A pilot randomized, multicenter, open-label, active comparator-controlled trial of a cp-690550-based regimen in de novo kidney allograft recipients
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Tofacitinib (Primary) ; Ciclosporin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Jan 2008 Status changed from recruiting to withdrawn prior to recruitment "due to re-evaluation of the overall risks and benefits of the proposed regimen in Study A3921037, taking into consideration the emerging findings from ongoing and completed clinical trials".
- 19 Nov 2007 New trial record.